

References:

1. 2021 Georgia Code Title 33 Insurance Chapter 20A - Managed Health Care Plans Article 2 - Patient's Right to Independent Review §33 -20A-31 Definitions. Justia US Law. Accessed April 25, 2023. <https://law.justia.com/codes/georgia/2021/title-33/chapter-20a/article-2/section-33-20a-31/>.
2. ProCysbi (cysteamine bitartrate) [package insert]. Lake Forest, IL: Horizon Therapeutics USA, Inc.; 2022.
3. Cystagon (cysteamine bitartrate) [package insert]. Morgantown, WV: Mylan Pharmaceuticals Inc; 2021.
4. Wilmer MJ, Schoeber JP, van den Heuvel LP, Levtchenko EN. Cystinosis: practical tools for diagnosis and treatment. *Pediatr Nephrol*. 2011;26(2):205-215. doi:10.1007/s00467-010-1627-6
5. Elmonem MA, Veys KR, Soliman NA, Dyck MV, Heuvel LPVD, Levtchenko E. Cystinosis: a review. *Orphanet Journal of Rare Diseases*. April 2016. doi:10.1186/s13023-016-0426-y
6. Bämner S, Weber LT. Nephropathic Cystinosis: Symptoms, Treatment, and Perspectives of a Systemic Disease. *Front Pediatr*. 2018;6:58. Published 2018 Mar 14. doi:10.3389/fped.2018.00058
7. Emma F, Nesterova G, Langman C, et al. Nephropathic cystinosis: an international consensus document. *Nephrol Dial Transplant*. 2014;29 Suppl 4(Suppl 4):iv87-iv94. doi:10.1093/ndt/gfu090
8. Nesterova G, Gahl WA. Cystinosis. 2001 Mar 22 [Updated 2017 Dec 7]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993 -2020. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1400/>
9. Bämner S, Weber LT. Conversion from immediate - to extended-release cysteamine may decrease disease control and increase additional side effects. *Pediatric Nephrology*. 2017;32(7):1281-1282. doi:10.1007/s00467-017-3618-3
10. Langman CB, Barshop BA, Deschênes G, et al. Controversies and research agenda in nephropathic cystinosis: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. *Kidney*